Astellas Pharma Hits Day Low Amid Price Pressure, Closes at JPY 2,136.50

Astellas Pharma, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 4.77% as of June 1, 2026. The stock reached an intraday low of JPY 2,136.50, reflecting a challenging trading session. In comparison to the Japan Nikkei 225, which gained 0.91% on the same day, Astellas Pharma's performance has been under pressure. Over the past week, the stock has decreased by 4.12%, while its monthly performance shows a decline of 1.5%. Despite these short-term setbacks, Astellas has demonstrated resilience over the past year, with a significant increase of 52.13%, although this is below the Nikkei's 76.3% rise. Financially, Astellas maintains a strong market position with a market capitalization of JPY 4,131,461 million and a return on equity of 18.31%. The company has shown impressive growth in net sales, reporting a 10.4% increase, and has consistently delivered positive results in recent quarters. The stock's current valuation reflects a price-to-book ratio of 2.34, indicating a premium compared to its peers.